Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483091 | 1.00 | GNPAT (0.47) | GNPATC3AR1NOD1FOLH1SLC6A5 | |
| SCHEMBL31751570 | 0.92 | C3AR1 (0.43) | GNPATC3AR1NOD1FOLH1SLC6A5 | |
| SCHEMBL12971400 | 0.92 | SLC6A5 (0.53) | GNPATNOD1FOLH1SLC6A5EPHX2 | |
| SCHEMBL12971402 | 0.92 | SLC6A5 (0.53) | GNPATNOD1FOLH1SLC6A5EPHX2 | |
| SCHEMBL17304346 | 0.90 | SLC6A5 (0.55) | GNPATNOD1FOLH1SLC6A5NPY1R | |
| SCHEMBL17304351 | 0.90 | SLC6A5 (0.55) | GNPATNOD1FOLH1SLC6A5NPY1R | |
| SCHEMBL12971327 | 0.90 | SLC6A5 (0.55) | GNPATNOD1FOLH1SLC6A5NPY1R | |
| SCHEMBL12971329 | 0.90 | SLC6A5 (0.55) | GNPATNOD1FOLH1SLC6A5NPY1R | |
| SCHEMBL7275349 | 0.90 | SLC6A5 (0.55) | GNPATNOD1FOLH1SLC6A5NPY1R | |
| SCHEMBL8741237 | 0.88 | GNPAT (0.50) | GNPATC3AR1NOD1FOLH1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117007703-A | Diagnostic marker for urinary calculus, diagnostic kit and application thereof | 中国人民解放军海军军医大学第一附属医院 | 2023-11-07 | — | — | CN | claimed |
| US-20030083380-A1 | Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging | YU RUEY J (US) | 2003-05-01 | — | — | US | claimed |
| US-5702688-A | TREATING SKIN DISORDERS | TRISTRATA TECHNOLOGY, INC. (US) | 1997-12-30 | — | — | US | claimed |
| US-5690967-A | MIXTURE CONTAINING AMPHOTERIC AGENT | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-25 | — | — | US | claimed |
| US-5684044-A | MIXED WITH AMPHOTERIC OR PSEUDOAMPHOTERIC AGENT | TRISTRATA, INCORPORATED (US) | 1997-11-04 | — | — | US | claimed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | claimed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | claimed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | claimed |
| US-10662394-B2 | Aqueous extraction process for the recovery of mucilage and demulsification | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190153353-A1 | AQUEOUS EXTRACTION PROCESS FOR THE RECOVERY OF MUCILAGE AND DEMULSIFICATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-3152219-B1 | METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPOID PHASES | NANOSCIENCE FOR LIFE GMBH & CO KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-9994464-B2 | Method and devices for de-emulsifying and complexing organic compounds in emulsions | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994464-B2 | Method and devices for de-emulsifying and complexing organic compounds in emulsions | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-5637615-A | ANTIAGING AGENT | TRISTRATA TECHNOLOGY, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0671162-A2 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5385938-A | application of mixtures containing hydroxyacetic acid(or its salts) to skin | IGI, INC. | 1995-01-31 | — | — | US | disclosed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | disclosed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | AGL, LIPA, MGLL | GNPAT 113/4885C3AR1 1202/4885NOD1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.